Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

In fact, median progression-free survival (PFS) decreased from 20.2 months with rucaparib (Rubraca) monotherapy to 15.0 months with the addition of nivolumab (Opdivo), translating into a hazard ratio ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

A wide selection of therapies are available to treat advanced prostate cancer, but the optimal treatment strategy is unknown.

Some PARP inhibitors include olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula). At the recent 8th Annual School of Nursing Oncology, Lai presented on the optimized use of PARP ...

The agents are rucaparib and olaparib, supported by the TRITON2 and PROfound studies, respectively. 1,2 Read More Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with ...